Master’s Programme in Life Science Technologies
Technology has revolutionized biomedicine, and experts in life science technologies can help shape healthcare systems and reduce the cost of production while making people healthier. Master’s Programme in Life Science Technologies educates a new generation of researchers, engineers, and entrepreneurs. The course emphasizes applied and fundamental knowledge of biological systems and phenomena. Graduates have a broad understanding of life science technologies and their applications. They are prepared for the next phase of life science research and innovation.
Molecular Life Science Technologies
Molecular Life Sciences Technologies use biochemistry and cell biology to understand the underlying processes affecting the environment and create solutions. Environmental hazards are as complex as human health and a comprehensive understanding of molecular processes is essential for developing sustainable losing strategies. By combining cellular biology and biochemistry, Molecular Life Science Technologies develops new and innovative solutions for a wide range of problems. Its graduates work in diverse fields and pursue many different career paths.
Although biotechnology and genetics are two fields that share many ethical and philosophical issues, Molecular Life Science Sciences has the distinct advantage of being directly concerned with life itself. This is a major drawback, however, as ethical concerns can arise during the course of instruction. While scientists and teachers may feel ill-prepared to discuss ethical or philosophical issues in class, collaboration with humanities professionals provides valuable perspectives. For example, students who study bioethics or ethics may find collaboration with scientists more useful.
Cell-based therapies
While cell-based therapies are a viable alternative to transplantation in many conditions, clinical success has been limited, in part because of problems associated with cell viability. These issues include poor retention at the site of injection and poor engraftment into damaged tissue. However, new research led by BME scientists is examining the use of a new delivery method to improve the cells’ ability to stick to damaged tissue.
CAR-T cells are a promising alternative. These cells are produced off the shelf and can be used in any patient with cancer. However, the process of developing them is time consuming, expensive, and logistically difficult. To develop them, scientists must genetically modify the patient’s own cells. In many cases, this can take years, and in many cases, costs are prohibitive. These are some of the challenges associated with using CAR-T cells.
Automation for cellular biology
The use of automation in cell culture has many benefits. It reduces the physical handling of cell cultures, which can cause contamination and inconsistent results. Automation systems such as the Olympus system, which was awarded a bronze prize at the 2021 Edison Awards, can also improve research efficiency by remotely scanning cells in culture vessels. Automated systems allow researchers to collect and analyze data in much less time. Listed below are some of the benefits of automation in cellular biology research.
Automated equipment is available that can simplify cell culture protocols and eliminate human error. Automation can also streamline complex processes, including reagent dispensing and cell washing. Automated robotic arms can even transfer microplates from incubators to microplate readers. Automation can save lab workers many hours of work, and it can cost more than $1 million for a complete process system. Automation also allows laboratories to conduct assays in evenings, when many researchers are working.
Bioproduction of high-value compounds
In the next 10 years, most of the vitamins and amino acids will be produced using biotechnological processes. Additionally, many specialty chemicals will be produced using biotechnological processes. Currently, using three process of technologies: biocatalysts, microbial fermentation, and cell cultures. This technology is also capable of producing bio-ethanol and bio-high-fructose corn syrup.
The biopharmaceutical industry has made multipurpose plants necessary to produce new pharmaceuticals and agrochemicals. In addition, the emergence of biopharmaceuticals has led to a marked increase in the demand for fine chemicals. Historically, the life sciences industry in USA has considered captive production of active ingredients to be their core competency, and outsourcing was typically used only for process complexity, capacity shortfalls, or new products with uncertain launches.
Biotechnology companies that utilize these technologies include Amphora, Delmar, NAEJA, and Attuite. Companies from the European region include Carbogen, and Molecular Systems. Companies in other countries include ChemBridge and ChemDiv, as well as Clauson-Kaas from Denmark. Among the many products produced using these technologies, monosodium glutamate and vitamin B2 are three of the most popular.